Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20012690 | 1.00 | HPGD (0.40) | HPGDSLC6A3L3MBTL1GAAALDH1A1 | |
| SCHEMBL11741223 | 0.88 | HPGD (0.35) | HPGDSLC6A3ALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL11777433 | 0.85 | HPGD (0.39) | HPGDL3MBTL1GAAALDH1A1POLB | |
| SCHEMBL11743390 | 0.84 | HPGD (0.34) | HPGDSLC6A3ALDH1A1 | |
| SCHEMBL6135613 | 0.83 | HPGD (0.38) | HPGDL3MBTL1GAAALDH1A1POLB | |
| SCHEMBL9376107 | 0.83 | EPHX1 (0.36) | HPGDALDH1A1 | |
| SCHEMBL19742949 | 0.83 | HPGD (0.37) | HPGDSLC6A3L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL11746420 | 0.83 | HPGD (0.37) | HPGDSLC6A3L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL13398845 | 0.83 | HPGD (0.37) | HPGDSLC6A3L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL22650371 | 0.82 | HPGD (0.32) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190275012-A9 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | LUPIN LIMITED (IN) | 2019-09-12 | — | — | US | disclosed |
| US-20190160045-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | LUPIN LTD (IN) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275012-A9 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | MALT1, PTP4A1, PTPRO | HPGD 3562/4885SLC6A3 2519/4885L3MBTL1 1778/4885 |
| US-20190160045-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | MALT1, PTP4A1, PTPRO | HPGD 3562/4885SLC6A3 2519/4885L3MBTL1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.